WO2020180093A3 - Oseltamivir-containing pharmaceutical composition - Google Patents

Oseltamivir-containing pharmaceutical composition Download PDF

Info

Publication number
WO2020180093A3
WO2020180093A3 PCT/KR2020/003030 KR2020003030W WO2020180093A3 WO 2020180093 A3 WO2020180093 A3 WO 2020180093A3 KR 2020003030 W KR2020003030 W KR 2020003030W WO 2020180093 A3 WO2020180093 A3 WO 2020180093A3
Authority
WO
WIPO (PCT)
Prior art keywords
oseltamivir
pharmaceutical composition
containing pharmaceutical
disclosed
pharmaceutically acceptable
Prior art date
Application number
PCT/KR2020/003030
Other languages
French (fr)
Korean (ko)
Other versions
WO2020180093A2 (en
Inventor
김상욱
임현태
송호준
김정태
Original Assignee
주식회사 코아팜바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 코아팜바이오 filed Critical 주식회사 코아팜바이오
Priority to MX2021010596A priority Critical patent/MX2021010596A/en
Publication of WO2020180093A2 publication Critical patent/WO2020180093A2/en
Publication of WO2020180093A3 publication Critical patent/WO2020180093A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a granule formulation comprising oseltamivir or pharmaceutically acceptable salts thereof.
PCT/KR2020/003030 2019-03-05 2020-03-04 Oseltamivir-containing pharmaceutical composition WO2020180093A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2021010596A MX2021010596A (en) 2019-03-05 2020-03-04 Oseltamivir-containing pharmaceutical composition.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190025018A KR20200106607A (en) 2019-03-05 2019-03-05 A pharmaceutical composition comprising oseltamivir
KR10-2019-0025018 2019-03-05

Publications (2)

Publication Number Publication Date
WO2020180093A2 WO2020180093A2 (en) 2020-09-10
WO2020180093A3 true WO2020180093A3 (en) 2020-12-10

Family

ID=72337809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/003030 WO2020180093A2 (en) 2019-03-05 2020-03-04 Oseltamivir-containing pharmaceutical composition

Country Status (3)

Country Link
KR (1) KR20200106607A (en)
MX (1) MX2021010596A (en)
WO (1) WO2020180093A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876719A (en) * 2021-11-02 2022-01-04 哈药集团技术中心 Oseltamivir dry syrup and preparation method thereof
KR20230173533A (en) * 2022-06-17 2023-12-27 주식회사 코아팜바이오 New composition of orodispersible powder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109020A (en) * 2006-04-04 2008-12-16 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 Oseltamivir phosphate granule and preparation method thereof
KR20090006062A (en) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 Methods of treating influenza viral infections
KR20100052262A (en) * 2008-11-10 2010-05-19 (주)아모레퍼시픽 Process for preparing powder comprising nanoparticles of sparingly soluble drug, powder prepared by same process and pharmaceutical composition comprising same powder
KR101628586B1 (en) * 2012-08-28 2016-06-08 (주)오리지날 바이오메디칼스 The controlled release method for a pharmaceutical composition composed of chelating complex micelles
KR20160084465A (en) * 2013-11-13 2016-07-13 버텍스 파마슈티칼스 인코포레이티드 Formulations of azaindole compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0759917T3 (en) 1995-02-27 2000-07-31 Gilead Sciences Inc Novel selective inhibitors of viral or bacterial neuraminidases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090006062A (en) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 Methods of treating influenza viral infections
KR20080109020A (en) * 2006-04-04 2008-12-16 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 Oseltamivir phosphate granule and preparation method thereof
KR20100052262A (en) * 2008-11-10 2010-05-19 (주)아모레퍼시픽 Process for preparing powder comprising nanoparticles of sparingly soluble drug, powder prepared by same process and pharmaceutical composition comprising same powder
KR101628586B1 (en) * 2012-08-28 2016-06-08 (주)오리지날 바이오메디칼스 The controlled release method for a pharmaceutical composition composed of chelating complex micelles
KR20160084465A (en) * 2013-11-13 2016-07-13 버텍스 파마슈티칼스 인코포레이티드 Formulations of azaindole compounds

Also Published As

Publication number Publication date
MX2021010596A (en) 2021-09-23
KR20200106607A (en) 2020-09-15
WO2020180093A2 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
EP4041734A4 (en) Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
EP4041733A4 (en) Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
WO2020180093A3 (en) Oseltamivir-containing pharmaceutical composition
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
WO2016196124A3 (en) Prodrugs comprising a pyroglutamate linker
MX2022003504A (en) Irak inhibitor and preparation method therefor and use thereof.
CA3042181C (en) Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives
IL276194B2 (en) Compounds or pharmaceutical compositions comprising them for use in the treatment of paininhibiting
WO2019194773A3 (en) The combination comprising linagliptin and metformin
EP4306113A3 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
EP3216450A8 (en) Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof
IL276311B2 (en) Methyllactam ring compound and pharmaceutical use thereof
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
EP4223759A4 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
EP3851438A4 (en) Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2019098572A3 (en) Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20766639

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20766639

Country of ref document: EP

Kind code of ref document: A2